Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas Pharma
Biotech
Astellas targets more deals, cost cutting to swerve patent cliff
Faced with a future of evaporating Xtandi sales, Astellas has set out ambitions to license fresh assets while also continuing to tighten its belt.
James Waldron
May 26, 2026 7:35am
Astellas appoints new top strategist—Chutes & Ladders
May 1, 2026 8:30am
Astellas thins early pipeline, swaps out struggling gene therapy
Apr 27, 2026 10:38am
Astellas, Dyno unearth $15M muscle disorder capsid
Apr 8, 2026 8:00am
Astellas axes early trial for Sjögren’s syndrome
Mar 30, 2026 2:18pm
Astellas ends $1.6B biobucks TCE pact with CytomX after 6 years
Mar 16, 2026 10:12am
